Fusion Pharmaceuticals Inc
1 day chart
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.
Buy US stocks in Australia starting with FUSN. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in FUSN
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.